Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan

Fibroblast growth factors (FGF) are a family of heparin‐binding angiogenic polypeptide mitogens. In the presence of heparin, recombinant human basic fibroblast growth factor (bFGF) is fully protected from tryptic digestion and partially protected from chymotryptic digestion. Complete protection of bFGF by heparin is achieved at ratios of growth factor:heparin of approximately 10 or less (w/w). The protection requires bioactive bFGF because inactivated bFGF is rapidly degraded by trypsin or chymotrypsin in the presence of heparin. The bFGF‐heparin interaction forms hydrophobic complexes which become insoluble in aqueous buffers at bFGF:heparin ratios of 8 to 10 (w/w). The heparin was found to bind up to a tenfold excess of bFGF on a weight basis. bFGF in the presence of heparin is as active as bFGF alone in inducing 3H‐thymidine incorporation into Swiss 3T3 fibroblast DNA.

[1]  M. Klagsbrun,et al.  Heparin affinity of anionic and cationic capillary endothelial cell growth factors: analysis of hypothalamus-derived growth factors and fibroblast growth factors. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Hascall,et al.  [45] Proteoglycans: Isolation and Characterization , 1982 .

[3]  N. Ling,et al.  Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[5]  N. Ling,et al.  Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. , 1986, Recent progress in hormone research.

[6]  A. Sommer,et al.  Production and characterization of human basic fibroblast growth factor from Escherichia coli. , 1988, The Journal of biological chemistry.

[7]  N. Ling,et al.  Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. , 1987, Biochemical and biophysical research communications.

[8]  J. Folkman,et al.  Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Schreiber,et al.  Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. , 1984, Science.

[10]  M. Klagsbrun,et al.  Multiple forms of basic fibroblast growth factor: amino-terminal cleavages by tumor cell- and brain cell-derived acid proteinases. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[12]  J. Fiddes,et al.  Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. , 1986, Science.

[13]  D. Gospodarowicz,et al.  Brain-derived fibroblast growth factor: a study of its inactivation. , 1983, Life sciences.

[14]  J. Folkman,et al.  Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. , 1984, Science.

[15]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[16]  D. Rifkin,et al.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation , 1988, The Journal of cell biology.

[17]  M. Karnovsky,et al.  Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group , 1986, The Journal of cell biology.

[18]  J. Harper,et al.  Purification of heparin-binding growth factors. , 1986, Analytical Biochemistry.

[19]  D. Gospodarowicz,et al.  Structural characterization and biological functions of fibroblast growth factor. , 1987, Endocrine reviews.

[20]  M. T. Brewer,et al.  A form of human basic fibroblast growth factor with an extended amino terminus. , 1987, Biochemical and biophysical research communications.

[21]  J. Kenney,et al.  Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Fiddes,et al.  Human basic fibroblast growth factor: nucleotide sequence and genomic organization. , 1986, The EMBO journal.

[23]  R. Hynes,et al.  Three different fibronectin mRNAs arise by alternative splicing within the coding region , 1983, Cell.

[24]  E. Levine,et al.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation. , 1983, Science.